Phase 3 Completed N=10 Treatment

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Source: ClinicalTrials.gov NCT01468584 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2014

Primary outcomePrimary: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 50.0 percentage of subjects achieving SVR

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who did not respond to previous treatment.

Outcome Measures

Outcome	Result	p-value
PRIMARY Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)	50.0	—

Eligibility Criteria

Inclusion Criteria

Genotype 2, chronic hepatitis C
Non-responders (patient who did not respond to previous treatment)
Able and willing to follow contraception requirements

Exclusion Criteria

Cirrhosis of the liver or hepatic failure
Hepatitis B surface antigen-positive or HIV antibodies-positive
History of, or concurrent hepatocellular carcinoma
History of, or concurrent depression, schizophrenia,; or suicide attempt in the past
Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01468584). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.